Ann: March 2024 Quarterly Report and Appendix 4C, page-6

• Strong CY23 OviTex™ PRS and OviTex sales, with TELA Bio, Inc. (‘TELA Bio’) reporting CY23
revenue of US$58.5 million (41% ‘pcp’
3 growth) and providing CY24 revenue guidance of US$74-
76 million (27-30% pcp growth).4
• Product shipments to TELA Bio continue to re-align with its sales trajectory (following a reduction
in shipments during H1 FY24) with H2 FY24 cash receipts from TELA Bio increasing 20% compared
to H1 FY24.
• US launch of OviTex IHR, a new AROA ECM™ product specifically designed for use in laparoscopic
& robotic-assisted inguinal hernia repair and co-developed with TELA Bio under the parties’
existing license arrangement.
• Enrolments completed for two clinical studies; the pilot study assessing Enivo™, AROA’s new
tissue apposition platform technology, and the Myriad Augmented Soft Tissue Regeneration
Registry (‘MASTRR’), AROA’s largest prospective study to date. AROA expects to commence
publishing study results from Q3 FY25. AROA’s Symphony™ randomised control trial continues
to progress well, with a total of 90 patients enrolled by the end of the quarter (n=120)

Wow, the writing is on the wall ... the chart is just the absolute perfect setup (volume diminishing to near zero lately also) - If you ever wanted to see TA in action look below - 680k shorts - not really that many but ARX only trades small volumes, so let's watch the bot action.

Let's see if there's a change in the wind from here.

It looks like ARX management finally got the message ... cash flow positive and increasing from here on hopefully!

Oops - sentiment - held!